All-in-One library prep kit, plus collection, stabilization and bioinformatics solutions enable NIPT and cancer research

Vancouver, Canada, and Hilden, Germany – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq® cfDNA All-in-One Kit, combining cell-free DNA extraction and library preparation in the first dedicated solution for liquid biopsy analysis on any next-generation sequencing (NGS) platform. The new kit integrates with QIAGEN’s recently launched PAXgene® Blood ccfDNA Tube for collection and stabilization of blood samples, as well as with the market’s first bioinformatics workflow for cfDNA also introduced today by QIAGEN, creating a streamlined testing solution that allows faster, more convenient and reliable analysis of cell-free DNA from sample collection to interpreted result.

Furthermore, QIAGEN unveiled an enhanced bioinformatics workflow for hereditary and rare diseases, offering unique capabilities for research using liquid biopsi